Background CD19 chimeric antigen receptor-T (CAR T) cell therapy has dramatically improved the outcomes for pediatric and adult patients with short-term complete remission (CR) rates of approximately 90% in relapsed/refractory B-lineage acute lymphoblastic leukemia (ALL) and objective response rates (ORRs)…
Introduction Chimeric antigen receptor (CAR)–modified T-cell immunotherapy is highly effective for patients with relapsed and/or refractory B-cell malignancies, but significant adverse effects remain a concern. Systemic cytokine release syndrome (CRS) can occur in association with the inflammatory cytokine surge during…
Introduction Chimeric antigen receptor (CAR)–modified T-cell immunotherapy can be a highly effective treatment for patients with relapsed and/or refractory hematologic malignancies, but significant adverse effects remain a concern. Systemic cytokine release syndrome (CRS) can occur in association with the inflammatory…
Cancer is among the leading causes of death worldwide. The number of new cancer cases per year is expected to rise to 23.6 million by 2030. Advancements in oncology therapeutics and associated improvements in survival mean that more patients may…
Acknowledgments COI disclosures: Dr. Lee serves on the external advisory board for Juno Therapeutics/Celgene, has provided ad hoc consulting to Harpoon Therapeutics, and has received clinical trial research support from Kite Introduction Chimeric antigen receptor (CAR) T-cell therapy has been…
Acknowledgments We thank ML Silverberg for assistance with development of nursing and postinfusion protocols. Screening Once identified as a candidate for chimeric antigen receptor (CAR) T-cell therapy, patients must undergo screening for eligibility. Prediagnostic evaluations are required to assess patient…
Introduction Chimeric antigen receptor (CAR) T-cells are one of the most rapidly growing cancer immunotherapies, particularly for B-cell malignancies. While the manufacturing of CAR T-cells is relatively straightforward, there are many barriers associated with the manufacturing process. Additionally, most CAR…
Conflicts of Interest The authors have no conflicts of interest to declare. The views expressed are the authors' own and do not represent the National Institutes of Health, the Department of Health and Human Services, or the US Federal government.…
Introduction Chimeric antigen receptor (CAR) T-cell immunotherapy is a rapidly emerging and highly publicized new treatment modality, which has gained significant attention for its effectiveness, side effects, and costs. Early-phase clinical trials have shown dramatic results in patients with often…
Plain Language Summary Breast cancer screening has been going on for many years now, and research suggests that most women in the community feel positive about screening as a way to reassure them that they are well or to find…